fashion -WSS

fashion

author：Wikipedia 2025-10-01 05:13:19 Page View：886

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Black vets could get higher VA benefits if race not used in lung test
Next article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

focus

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Class action alleges UnitedHealth concealed DOJ probe

AdobeYou’rereadingthewebversionofHealthCareInc.,STAT’sweeklynewsletterfollowingtheflowofmoneyinmedic

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

DarronCummings/APLONDON—AU.K.governmentagencyonTuesdaysaidthatitwon’trecommendEliLilly’sMounjaro—par

fashion

leisure time

focus

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes